局部晚期非小细胞肺癌同步放化疗期间早期影像学与代谢肿瘤反应评估
研究纳入276例接受同步放化疗的局部晚期非小细胞肺癌患者,分析诱导化疗前后PET/CT提取的肿瘤体积、球形度和SUVpeak对失败模式的预测价值。中位随访7.6年,鳞癌较非鳞癌有更高的局部区域失败风险且远处转移风险更低;诊断时高SUVpeak与两种病理类型更高的局部区域失败风险相关;鳞癌中体积缩小较少与远处转移风险升高相关。
要点
- 鳞癌局部区域失败风险高于非鳞癌(sHR=2.771),远处转移风险低于非鳞癌(sHR=0.247)。
- 诊断时高SUVpeak与鳞癌和非鳞癌更高的局部区域失败风险相关。
- 鳞癌中肿瘤体积缩小较少与远处转移风险升高相关。
核心结论
- 鳞癌中疾病体积反应差与更高的远处转移风险相关,未观察到其他明确的反应与失败模式的相关性。
- 病理类型与失败模式显著相关,鳞癌倾向于以局部区域失败为首发部位,非鳞癌倾向于以远处转移为首发部位。
- 诊断时高SUVpeak增加两种病理类型的局部区域失败风险。
研究设计与样本
- 回顾性纳入276例接受同步放化疗的局部晚期非小细胞肺癌患者。
- 将放疗计划PET/CT与诊断PET/CT的靶区配准,其间患者接受诱导化疗。
- 从每次扫描中提取肿瘤体积、球形度和SUVpeak。
- 首次失败部位分为局部区域失败、远处转移或同时局部区域加远处转移。
- 采用Fine和Gray模型分析失败模式,包括基线模型(体能状态、分期、组织学)、鳞癌影像模型和非鳞癌影像模型。
主要发现
- 中位随访7.6年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of early treatment response for patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemo-radiotherapy (cCRT) is unclear. The study aims to investigate the predictive value of response to induction chemotherapy (iCX) and the correlation with pattern of failure (PoF). MATERIALS AND METHODS: Patients with LA-NSCLC treated with cCRT were included for analyses (n = 276). Target delineations were registered from radiotherapy planning PET/CT to diagnostic PET/CT, in between which patients received iCX. Volume, sphericity, and SUVpeak were extracted from each scan. First site of failure was categorised as loco-regional (LR), distant (DM), or simultaneous LR+M (LR+M). Fine and Gray models for PoF were performed: a baseline model (including performance status (PS), stage, and histology), an image model for squamous cell carcinoma (SCC), and an image model for non-SCC. Parameters included PS, volume (VOL) of tumour, VOL of lymph nodes, ΔVOL, sphericity, SUVpeak, ΔSUVpeak, and oligometastatic disease. RESULTS: Median follow-up was 7.6 years. SCC had higher sub-distribution hazard ratio (sHR) for LRF (sHR = 2.771 [1.577:4.87], p < 0.01) and decreased sHR for DM (sHR = 0.247 [0.125:0.485], p < 0.01). For both image models, high diagnostic SUVpeak increased risk of LRF (sHR = 1.059 [1.05:1.106], p < 0.01 for SCC, sHR = 1.12 [1.03:1.21], p < 0.01 for non-SCC). Patients with SCC and less decrease in VOL had higher sHR for DM (sHR = 1.025[1.001:1.048] pr. % increase, p = 0.038). CONCLUSION: Poor response in disease volume was correlated with higher sHR of DM for SCC, no other clear correlation of response and PoF was observed. Histology significantly correlated with PoF with SCC prone to LRF and non-SCC prone to DM as first site of failure. High SUVpeak at diagnosis increased the risk of LRF for both histologies.
引用
- Tvilum M, Knap MM, Hoffmann L, et al. Early radiologic and metabolic tumour response assessment during combined chemo-radiotherapy for locally advanced NSCLC. Clin Transl Radiat Oncol. 2024. PMID: 38317680. doi:10.1016/j.ctro.2024.100737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。